康莱特注射液辅助治疗非小细胞肺癌的疗效观察

Efficacy Observation of Kanglaite Injection for Non-small Cell Lung Cancer

目的:观察康莱特注射液辅助治疗非小细胞肺癌(NSCLC)的临床疗效。方法:选择我所2010-2011年收治的NSCLC患者共114例,随机分为治疗组(58例)和对照组(56例)。两组患者均根据自身肿瘤的分期决定NSCLC的治疗方案;治疗组患者在此基础上加用康莱特注射液100ml静脉滴注,qd。两组均21d为1个周期,治疗2个周期。按世界卫生组织(WHO)实体瘤疗效评价标准评价近期疗效;按Karnofsky功能状态评分标准评价生存质量;按WHO抗癌药物急性及亚急性毒性反应分度标准评价不良反应。结果:化疗2个周期后,治疗组患者的有效率、疾病控制率显著高于对照组;治疗组患者在生存质量改善、稳定进展方面均显著优于对照组(P<0.05);治疗组各项不良反应发生率均低于对照组(P<0.05)。结论:康莱特注射液辅助治疗NSCLC较为安全、有效。

OBJECTIVE： To observe clinical efficacy of Kanglaite injection for non-small cell lung cancer （NSCLC）. METHODS： 114 NSCLC patients in our hospital during 2010--2011 were selected and divided into treatment group （58 cases） and control group （56 cases）. Therapeutic scheme for NSCLC was determined in two groups according to staging of tumor. Treatment group was additionally given Kanglaite injection 100 ml intravenously, qd. A treatment course lasted for 21 d, and two groups both received 2 course of treatment. Shot-term efficacies were evaluated according to evaluation criteria for solid tumor issued by WHO; KPS scoring criteria was adopted for evaluation of quality of life; according to acute and subacute toxicity evaluation criterion for WHO anticancer drug, adverse drug reactions were evaluated. RESULTS： After 2 courses of chemotherapy, the effective rate and disease control rate of treatment group were significantly higher than those of control group; the improvement and stability of life quality in treatment group was better than in control group, and the progress was significantly lower than in control group; adverse drug reactions were lower than in control group （P〈0.05）. CONCLUSION： Kanglaite injection on NSCLC clinical treatment can play a good role in support.